CAR-T Ed ForumCLL Society’s Overview of Programs and Services Recorded Wednesday, April 21, 2021 https://www.youtube.com/watch?v=J7QglhJ174Y Continue to Panel Q & A CLL Society Resources Download Slides CAR-T Webpage CLL Society Webinar
CAR-T Ed ForumCAR-T and CLL: A Patient and Caregiver Journey Recorded Wednesday, April 21, 2021 https://youtu.be/-2duh-jA3ZU Continue to Session 2: Immunotherapy: A New Paradigm for Treatment CLL Society Resources Download Slides
CAR-T Ed Forum: Welcome and Introductions Recorded Wednesday, April 21, 2021 https://youtu.be/JcQzgxI8ga0 Continue to Session 1: CAR-T and CLL: A Patient and Caregiver Journey CLL Society Resources Download Slides CAR-T Webpage
Dr. Utkarsh H. Acharya, DO, FACP took great care of me during my CAR-T therapy as an outpatient at the Seattle Cancer Care Alliance (SCCA)/HUTCH and as an inpatient twice at
Brian posts on his CAR-T blog and the grief and joy in the CLL world. Also more on swimming.
I want to introduce a remarkable young physician who you will be hearing more from in the future. Dr. Utkarsh H. Acharya, DO, FACP is now the Program Director, Hematology-Oncology Fellowship
Take Away Points: As the CAR-T technology improves, new targets for many cancers are being researched and identified. When the re-infused T cells recognize our cancer, they activate and release large
Take Away Points: CAR-T (Chimeric Antigen Receptor T-cell) is a cellular immune therapy using our own T cells that have been educated to recognize and attack our cancer. The target of
Following discontinuation of a non-covalent Bruton tyrosine kinase inhibitor (BTKi), venetoclax is clinically active in patients with CLL or Richter transformation who have not received it in the past. CAR-T therapy may also be an option, but this requires further study.
